Piperacillin-tazobactam linked to higher mortality than cefepime in Pseudomonas pneumonia

A single-center retrospective cohort study compared piperacillin-tazobactam and cefepime in 204 patients with Pseudomonas aeruginosa pneumonia using overlap-weighted analyses. The study reported higher 30-day all-cause mortality with piperacillin-tazobactam (23.1%) than cefepime (11.5%), while a composite desirability of outcome ranking, resistance development, clinical success, and acute kidney injury rates were similar between groups. The authors state that sample size limits interpretation and that the mortality finding warrants further investigation in larger studies.

Most relevant for: Clinicians managing hospitalized patients with Pseudomonas aeruginosa pneumonia who are selecting between piperacillin-tazobactam and cefepime.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.